Abstract
Introduction
Many colonoscopies following a positive fecal immunochemical test (FIT) will not identify a probable cause for fecal blood, and missed neoplasia is a concern. The study determined whether the absence of neoplasia at a FIT positive diagnostic colonoscopy was due to a missed lesion and whether the initial FIT hemoglobin (f-Hb) concentration could predict missed lesions.
Methods
This was a retrospective audit of patients who had undergone diagnostic colonoscopy after FIT screening (2 sample ≥ 20 µg Hb/g feces). Probable bleeding lesions including cancer, advanced adenoma, colitis, and angiodysplasia were considered a “positive colonoscopy outcome.” For those with a negative outcome, findings at the subsequent colonoscopy were assessed.
Results
There were 1087 good quality colonoscopies within 12 months of a positive FIT. In total, 171 (15.7%) patients had a positive outcome at the diagnostic colonoscopy. Subsequent colonoscopies of negative outcome cases (n = 418, median of 3.1y later) were reviewed; of these, there were 57 (13.6%) cases with a positive outcome. This included CRC in 0.5% (n = 2) and advanced adenoma in 11.7% (n = 49). High f-Hb and having both FIT samples ≥ 20 µg/g feces were associated with a positive outcome at the original diagnostic colonoscopy (p < 0.05). However, f-Hb was not predictive for a positive outcome at the subsequent colonoscopy by either maximum f-Hb (p = 0.768), total f-Hb (p = 0.459), or both FIT samples ≥ 20 µg/g (p = 0.091).
Conclusion
A small proportion of “false” positive FIT results had cancer or advanced adenoma found at the subsequent colonoscopy. A missed lesion could not be predicted by the initial FIT f-Hb.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. https://doi.org/10.1002/ijc.29210.
Chiu HM, Chen SL, Yen AM et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221–3229. https://doi.org/10.1002/cncr.29462.
Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371. https://doi.org/10.1056/NEJM199305133281901.
Young GP, Symonds EL, Allison JE et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci. 2015;60:609–622. https://doi.org/10.1007/s10620-014-3445-3.
Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med. 2019;170:319–329. https://doi.org/10.7326/M18-2390.
AIHW, Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program. 2018: Australian Institute of Health and Welfare Canberra.
Gini A, Jansen EEL, Zielonke N et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: a systematic review. Eur J Cancer. 2020;127:224–235. https://doi.org/10.1016/j.ejca.2019.12.014.
Cole SR, Tucker GR, Osborne JM et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.
Brenner H, Werner S. Selecting a cut-off for colorectal cancer screening with a fecal immunochemical test. Clin Transl Gastroenterol. 2017;8:e111. https://doi.org/10.1038/ctg.2017.37.
Kim NH, Park JH, Park DI et al. Are hemorrhoids associated with false-positive fecal immunochemical test results? Yonsei Med J. 2017;58:150–157. https://doi.org/10.3349/ymj.2017.58.1.150.
Kim NH, Jung YS, Lim JW et al. Yield of repeat colonoscopy in asymptomatic individuals with a positive fecal immunochemical test and recent colonoscopy. Gastrointest Endosc. 2019;89:1037–1043. https://doi.org/10.1016/j.gie.2019.01.012.
Lee J, Park SW, Kim YS et al. Risk factors of missed colorectal lesions after colonoscopy. Medicine (Baltimore). 2017;96:e7468. https://doi.org/10.1097/MD.0000000000007468.
Rivero-Sanchez L, Grau J, Auge JM et al. Colorectal cancer after negative colonoscopy in fecal immunochemical test-positive participants from a colorectal cancer screening program. Endosc Int Open. 2018;6:E1140–E1148. https://doi.org/10.1055/a-0650-4296.
Ribbing Wilen H, Blom J, Hoijer J et al. Fecal immunochemical test in cancer screening: colonoscopy outcome in FIT positives and negatives. Scand J Gastroenterol. 2019;54:303–310. https://doi.org/10.1080/00365521.2019.1585569.
Cock C, Anwar S, Byrne SE et al. Low sensitivity of fecal immunochemical tests and blood-based markers of DNA hypermethylation for detection of sessile serrated adenomas/polyps. Dig Dis Sci. 2019. https://doi.org/10.1007/s10620-019-05569-8.
Garcia M, Mila N, Binefa G et al. Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: are we there yet? Eur J Cancer Prev. 2015;24:321–327. https://doi.org/10.1097/CEJ.0000000000000090.
Kim NH, Kwon MJ, Kim HY et al. Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia. Dig Liver Dis. 2016;48:667–672. https://doi.org/10.1016/j.dld.2016.03.001.
Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust. 2002;176:155–157.
Ciatto S, Martinelli F, Castiglione G et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer. 2007;96:218–221. https://doi.org/10.1038/sj.bjc.6603534.
Fenocchi E, Gaggero P, Rondán M et al. Usefulness of the fecal immunochemical test in the detection of advanced adenomas in subjects at average risk for colorectal cancer. Endoscopia. 2015;27:64–68.
Australian Bureau of Statistic. Socio-economic Indexes for Areas: Technical Paper, 2016. 2016; cat. no. 2033.0.55.001:[
Symonds EL, Fraser CG, Bastin D, Berwald G, Young GP. The effect of the variability in fecal immunochemical test sample collection technique on clinical performance. Cancer Epidemiol Biomarkers Prev. 2020. https://doi.org/10.1158/1055-9965.EPI-20-0984.
Liao CS, Lin YM, Chang HC et al. Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. World J Gastroenterol. 2013;19:8366–8372. https://doi.org/10.3748/wjg.v19.i45.8366.
Auge JM, Pellise M, Escudero JM et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology. 2014;147:e1. https://doi.org/10.1053/j.gastro.2014.06.008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hunt, J.S., Cock, C. & Symonds, E.L. A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test. Dig Dis Sci 67, 1843–1849 (2022). https://doi.org/10.1007/s10620-021-06986-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-021-06986-4